Free Trial
NASDAQ:MLYS

Mineralys Therapeutics Q2 2025 Earnings Report

Mineralys Therapeutics logo
$14.23 -0.11 (-0.77%)
Closing price 04:00 PM Eastern
Extended Trading
$14.22 -0.01 (-0.04%)
As of 05:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mineralys Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.78
Beat/Miss
N/A
One Year Ago EPS
N/A

Mineralys Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Mineralys Therapeutics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 12, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Mineralys Therapeutics Earnings Headlines

This Could Be the Most Profitable Season of Your Life
Institutional money is pouring in. Bitcoin ETFs are live. Altcoin adoption is accelerating. This is the same point in every cycle when crypto enters its most explosive phase — and two experts are showing how to ride it. Inside The Crypto Code Workshop, you’ll get their step-by-step system and $10 in free Bitcoin for attending.
See More Mineralys Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Mineralys Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mineralys Therapeutics and other key companies, straight to your email.

About Mineralys Therapeutics

Mineralys Therapeutics (NASDAQ:MLYS) is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for fibroinflammatory diseases of the liver and kidney. The company’s proprietary platform centers on small-molecule soluble guanylate cyclase (sGC) modulation, aiming to restore normal vascular and immune cell function to address underlying drivers of chronic organ damage. Mineralys’ lead programs include MLY-402 for portal hypertension secondary to cirrhosis and MLY-127 for diabetic kidney disease, both of which have advanced into clinical studies.

Since its inception, Mineralys has built a diversified pipeline that spans from early discovery through Phase 2 development. The research team leverages in-house target validation, medicinal chemistry, and translational biology capabilities to optimize sGC modulators with differentiated pharmacokinetic and safety profiles. Beyond its lead assets, the company is exploring additional indications where impaired nitric oxide signaling and fibrosis intersect, including nonalcoholic steatohepatitis (NASH) and select rare kidney disorders.

Headquartered in Cambridge, Massachusetts, Mineralys operates research facilities in the Boston biotech hub while maintaining collaborations with leading academic institutions and contract research organizations worldwide. This geographic reach enables the company to conduct multi-center clinical trials across North America and Europe, accelerating patient enrollment and regulatory interactions. The global footprint also supports future commercial readiness in key markets.

Mineralys is led by an experienced management team with deep industry expertise spanning drug discovery, clinical development, regulatory affairs, and commercialization. The leadership includes veterans from both large pharmaceutical companies and successful biotech startups, supported by a scientific advisory board of renowned hepatology and nephrology experts. Together, they guide Mineralys toward its mission of delivering first-in-class therapies for patients with debilitating liver and kidney diseases.

View Mineralys Therapeutics Profile

More Earnings Resources from MarketBeat